Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genprex, Inc. (GNPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7700+0.2700 (+18.00%)
At close: 04:00PM EDT
1.7700 0.00 (0.00%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close1.5000
Open1.5000
Bid1.8000 x 900
Ask1.7700 x 900
Day's Range1.5000 - 1.7900
52 Week Range1.1700 - 3.6200
Volume288,978
Avg. Volume104,193
Market Cap84.78M
Beta (5Y Monthly)-0.51
PE Ratio (TTM)N/A
EPS (TTM)-0.3950
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GNPX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genprex, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/08/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • PR Newswire

    Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that Company manufacturing leadership will present sessions on cutting edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit taking place from July 19-21, 2022 in Boston.

  • PR Newswire

    Genprex to Present at Upcoming June Investor Conferences

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in June 2022.

  • PR Newswire

    Genprex to Present at Upcoming Investor Conference in May 2022

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes to investors at the following conference in May 2022.

Advertisement
Advertisement